Zacks Research Issues Optimistic Outlook for MD Earnings

Pediatrix Medical Group, Inc. (NYSE:MD) – Analysts at Zacks Research upped their Q1 2027 earnings estimates for shares of Pediatrix Medical Group in a research note issued on Tuesday, August 18th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.37 per share for the quarter, up from their previous forecast of $0.34. The consensus estimate for Pediatrix Medical Group’s current full-year earnings is $2.15 per share. Zacks Research also issued estimates for Pediatrix Medical Group’s Q3 2027 earnings at $0.57 EPS, Q4 2027 earnings at $0.63 EPS, FY2027 earnings at $2.10 EPS, Q1 2028 earnings at $0.34 EPS, Q2 2028 earnings at $0.49 EPS and FY2028 earnings at $2.04 EPS.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $487.78 million during the quarter, compared to analysts’ expectations of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. Pediatrix Medical Group’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the business earned $0.53 EPS.

MD has been the subject of several other research reports. Jefferies Financial Group cut Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their price objective for the company from $27.00 to $28.00 in a report on Wednesday. Weiss Ratings raised shares of Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. UBS Group raised their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a report on Friday, May 8th. Finally, Truist Financial upped their price objective on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.00.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $26.22 on Thursday. Pediatrix Medical Group has a twelve month low of $15.69 and a twelve month high of $27.94. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.45. The company has a market cap of $2.13 billion, a PE ratio of 12.55 and a beta of 0.66. The company’s 50 day moving average is $25.68 and its 200 day moving average is $22.91.

Hedge Funds Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its holdings in shares of Pediatrix Medical Group by 23.8% in the first quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock valued at $320,000 after purchasing an additional 4,247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Pediatrix Medical Group by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock worth $743,000 after purchasing an additional 2,251 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Pediatrix Medical Group by 4.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock worth $3,891,000 after purchasing an additional 12,171 shares during the period. Cetera Investment Advisers acquired a new position in Pediatrix Medical Group in the 2nd quarter valued at about $145,000. Finally, Quantbot Technologies LP acquired a new position in Pediatrix Medical Group in the 2nd quarter valued at about $99,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.